⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
INBX News
Inhibrx Biosciences, Inc. Common Stock
Form 8-K
sec.gov
INBX
Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study
prnewswire.com
INBX
Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study
prnewswire.com
INBX
Chondrosarcoma Clinical Trial Pipeline: Emerging Therapies and Key Developments Shaping the Treatment Landscape | DelveInsight
globenewswire.com
INBX
LLY
PFE
NVS
BMY
EXEL
JNJ
AZN
JAZZ
TLRY
Form 8-K
sec.gov
INBX
Form 8-K
sec.gov
INBX
Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million
prnewswire.com
INBX
Form 8-K
sec.gov
INBX
Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma
prnewswire.com
INBX
Form 8-K
sec.gov
INBX